PD-1抗体联合抗血管生成靶向治疗在晚期复发转移头颈部肿瘤中的探索研究

目的:观察PD-1抗体联合抗血管靶向治疗在晚期复发转移头颈部肿瘤中的疗效和耐受情况。方法:回顾性分析使用PD-1单抗抗体联合抗血管靶向治疗的4例晚期复发转移头颈部肿瘤患者的临床资料,采用RECIST 1.1标准评价4例患者的疗效,并观察其治疗的耐受情况。结果:使用PD-1单抗抗体联合抗血管靶向治疗的4例患者1例达CR,1例达PR,1例虽SD但病灶缩小,症状缓解,1例PD,用药期间均未出现有出血现象,患者对治疗的总体耐受性良好,未出现明显的3~4级不良反应。结论:PD-1抗体联合抗血管靶向治疗是晚期复发转移头颈部肿瘤治疗的新选择,且耐受性良好。

Exploration and Study of PD-1 Antibody Combined with Anti-angiogenesis Targeted Therapy in Advanced Recurrent and Metastatic Head and Neck Tumors

Objective:To observe the efficacy and tolerance of PD-1 antibody combined with anti-vascularized targeted therapy in advanced recurrent metastatic head and neck tumors.Methods:The clinical data of 4 patients with advanced recurrence and metastatic head and neck tumors treated with PD-1 monoclonal antibody combined with anti-vascular targeted therapy were retrospectively analyzed.RECIST 1.1 was used to evaluate the efficacy of 4 patients and observe their tolerance to treatment.Results:In the 4 patients treated with PD-1 monoclonal antibody combined with anti-vessel targeted therapy,1 patient achieved CR,1 patient achieved PR,1 patient showed focal shrinkage and symptom relief despite SD,and 1 patient showed PD.No bleeding occurred during the medication,and the overall tolerance of the patients to the treatment was good,with no significant grade 3-4 adverse reactions.Conclusion:PD-1 antibody combined with anti-vascular targeted therapy is a new choice for the treatment of head and neck tumors with advanced recurrence and metastasis,and it is well tolerated.